Related Experiment Video
Updated: Oct 14, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Prognostic significance of pre-intervention circulating cytokines in digestive system cancers: a systematic review
Fatemeh Tajik1,2, Fereshteh Rezagholizadeh3,4, Mahdieh Razmi5,6
1Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Background:
Circulating cytokines can influence tumor progression and immune evasion, serving as non-invasive biomarkers in digestive system (DS) cancers. This study evaluates the prognostic significance of biofluid cytokines in DS cancers.
Methods:
Comprehensive literature search in various databases identified studies reporting the prognostic importance of serum or plasma cytokines based on multivariate data, focusing on overall survival (OS) and disease/relapse/progression-free/cancer-specific-survivals (DFS/RFS/PFS/CSS). Quality assessment was done using the Newcastle-Ottawa scale. Heterogeneity was evaluated through Chi-square-based Q and I2 analyses. Publication bias was assessed via funnel plots, Egger's, Begg's, and trim-and-fill methods, alongside subgroup and sensitivity analyses.
Results:
A total of 42 articles evaluating 7 blood cytokines in DS cancers were included, with IL-6 and the CXCL family being the most studied. Elevated IL-6 levels were significantly associated with poor survival outcomes in esophageal, hepatocellular, biliary tract, pancreatic, and colorectal cancers for both OS and DFS/RFS/PFS/CSS. High CXCL levels correlated with worse prognosis in colorectal (OS: HR = 2.019) and hepatocellular (OS: HR = 5.569, DFS/RFS/PFS/CSS: HR = 1.610) cancer patients. Higher CCL levels predicted poor OS (HR = 1.912) in colorectal cancer. Circulating IL-10, IL-1β, and TNF-α showed no significant correlation with survival outcomes in DS. Subgroup analyses revealed varying prognostic significances of each cytokine in different DS malignancies. Publication bias was minimal except for IL-6 in pancreatic carcinoma, affirming the robustness of most outcomes.
Conclusion:
Elevated circulating IL-6, CXCL, and CCL families may predict poor prognosis in certain DS, highlighting their potential as prognostic markers. Further studies are needed to translate these findings into clinical practice.
Prospero Registration Number:
CRD42022316733.